Remdesivir, A Potential Drug for COVID-19 Treatment: A New Hope

Author(s): Kuldeep Singh, Dilpreet Singh*, Karan Razdan

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 8 , 2021


Article ID: e260721189256
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Objective: Coronavirus Disease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of Severe Acute Respiratory Syndrome (SARS).

Methods: Currently, many drugs/therapies have been tested for COVID-19, which responded sub- -optimally to the patients. Remdesivir is an RNA polymerase inhibitor that found promising results in ongoing clinical trials and shows a faster recovery rate in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients.

Results: In this review, we discussed a brief overview of biopharmaceutical and pharmacological aspects of Remdesivir. Moreover, the ongoing regulatory status of Remdesivir by official bodies has also been described.

Keywords: Remdesivir, COVID-19, USFDA, SARS, WHO, RNA polymerase inhibitor.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 8
Year: 2021
Published on: 18 December, 2020
Article ID: e260721189256
Pages: 3
DOI: 10.2174/2666796701999201218141652

Article Metrics

PDF: 20